• Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content


Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

ASCO 2018 HCC TRACK

SPOTLIGHT ON HEPATOCELLULAR CARCINOMA

By: Anne John Michael | Last updated: 10th June 2018 | In: ASCO 2018 Annual Meeting, Chemotherapy, Conferences, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Targeted Therapies, Translational Research

ASCO 2018 HCC Keywords

#ASCO18, apatinib, atezolizumab, Avastin, AXL, Bayer, bevacizumab, cabozantinib, CELESTIAL, cMET, Cometriq, Cyramza, doxorubicin, Eisai, Eli Lilly, Exelixis, Genentech, icaritin, Imclone, Keytruda, lenvatinib, Lenvima, Merck, MSD, Nexavar, PD-1, PD-L1, pembrolizumab, ramucirumab, REACH-2, Roche, SHR-1210, sorafenib, TACE, Tecentriq, TMB, VEGF, VEGFR

Hepatocellular carcinoma (HCC) is a rapidly deteriorating malignancy with poor prognosis. Since the introduction of sorafenib (SHARP and the Asia Pacific studies) a decade ago, successes with novel agents have been scarce. This year’s American Society of Clinical Oncology (ASCO) annual meeting included two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

NEW EVIDENCE FOR SECOND-LINE TARGETED THERAPIES IN ADVANCED HCC

In the randomised Phase III REACH-2 study (NCT02435433), ramucirumab significantly improved median overall survival (OS) (8.5 months) of patients with advanced HCC and elevated alpha-fetoprotein when compared to placebo (7.3 months) in the second-line treatment of HCC (P=0.0199).1 The VEGFR2-directed monoclonal antibody (MAb) also significantly improved median progression-free survival (PFS) (2.8 months vs 1.6 months for placebo); P<0.0001), as well as increased the objective response rate (ORR) (4.6% vs 1.1% for placebo; P=0.1156) and disease control rate (DCR) (59.9% vs 38.9% for placebo; P=0.0006).1

CELESTIAL (NCT01908426), another Phase III randomised trial in the second-line treatment of HCC, revealed that cabozantinib, a small molecule inhibitor of MET, the VEGF receptors, and AXL, significantly improved median OS (10.2 months vs 8.0 months for placebo; P=0.0049) and median PFS (5.2 months vs 1.9 months for placebo; P<0.0001) for previously treated patients with advanced HCC.2 Subgroup analysis showed improved efficacy of cabozantinib, in both patients younger than 65 years as well as patients 65 years and older.3 Hepatitis B virus (HBV) was associated with HCC in patients younger than 65 years. The distribution of hepatitis C virus (HCV) was evenly distributed over the two age groups. Another subgroup analysis looked at CELESTIAL patients who received sorafenib as the only prior systemic therapy; cabozantinib improved the OS and PFS, an effect irrespective of the duration of sorafenib treatment.4

ADVANCES IN IMMUNOTHERAPY

The ASCO 2018 HCC track contained two studies that independently showed anti-tumour activity of pembrolizumab in the second-line for advanced liver cancer. Preliminary data from the open-label, Phase II KEYNOTE-224 trial (NCT02702414) indicated an ORR of 16.3% to pembrolizumab, an immunotherapy medication.5 The trial also revealed that at 12 months, pembrolizumab had a PFS rate of 25.4% and OS rate of 53.6%.5 Notably, in the KEYNOTE-224, 21% were HBV carrier and 26% were HCV carrier. Another Phase II trial showed a median time to tumour progression of 3 months and median OS of 14 months.6

Japanese investigators of the SCRUM-Japan GI-SCREEN study (UMIN000016343) looked at tumour mutation burden (TMB) in advanced gastrointestinal (GI) malignant tissue samples (N=1,759) in the Cancer Genome Atlas (TCGA) to determine which patients may confer benefit from immunotherapy.7 Twenty-seven (1.5%) HCC samples were included of which 7% were found to be TMB-high.7


Newsletter Sign-Up

Do you like our ASCO 2018 HCC coverage? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Newsletter

YOU MAY ALSO LIKE

Dosing issues with DOACs in Asian real world setting

Dosing issues with DOACs in Asian real world setting

https://ftp.medi-paper.com/wp-content/uploads/2021/12/Dosing-issues-with-DOACs-in-Asian-real-world-setting.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-12-23 18:58:462022-02-18 10:04:38Dosing issues with DOACs in Asian real world setting
Sotorasib approved as the first targeted therapy for Lung Cancer

Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer

https://ftp.medi-paper.com/wp-content/uploads/2021/11/Sotorasib-approved-as-the-first-targeted-therapy-for-Lung-Cancer.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-11-22 11:35:262022-01-13 13:51:11Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer
Amivantamab in combination with Lazertinib showed efficacy in NSCLC

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2021/11/Amivantamab-in-combination-with-Lazertinib-showed-efficacy-in-NSCLC.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-11-22 11:05:252022-01-11 11:49:24Amivantamab in combination with Lazertinib showed efficacy in NSCLC
ASCO GI Webinar Update on NET and HCC_Ipsen

ASCO GI Webinar: Update on NET and HCC

https://ftp.medi-paper.com/wp-content/uploads/2021/10/ASCO-GI-Webinar-Update-on-NET-and-HCC_Ipsen-1.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-10-07 11:48:162021-11-04 09:28:12ASCO GI Webinar: Update on NET and HCC
PreviousNext
Dosing issues with DOACs in Asian real world setting
23rd December 2021

Dosing issues with DOACs in Asian real world setting

Sotorasib approved as the first targeted therapy for Lung Cancer
22nd November 2021

Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer

Figure 1. Data of selected Phase II and III ASCO 2018 HCC studies

AFP=alpha-fetoprotein; BCLC=Barcelona Clinic Liver Cancer staging; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; EHS=extrahepatic spread; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; NR=not reported; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TTP=time to progression; VI=vascular invasion.

" itemprop="thumbnailUrl">Figure 1. Data of selected Phase II and III ASCO 2018 HCC studies

AFP=alpha-fetoprotein; BCLC=Barcelona Clinic Liver Cancer staging; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; EHS=extrahepatic spread; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; NR=not reported; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TTP=time to progression; VI=vascular invasion.

" itemprop="thumbnailUrl" alt="ASCO2018 HCC ASCO18 hepatocellular carcinoma liver cancer keytruda pembrolizumab atezolizumab tecentriq cabozantinib levantinib ramucirumab REACH-2 CELESTIAL KEYNOTE-224" height="846" width="1500" srcset="https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1.png 1500w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1-300x169.png 300w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1-768x433.png 768w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1-1030x581.png 1030w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1-705x398.png 705w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-1-450x254.png 450w" sizes="(max-width: 1500px) 100vw, 1500px">
©MediPaper Medical Communications Ltd

Figure 1. Data of selected Phase II and III ASCO 2018 HCC studies

AFP=alpha-fetoprotein; BCLC=Barcelona Clinic Liver Cancer staging; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; EHS=extrahepatic spread; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; NR=not reported; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TTP=time to progression; VI=vascular invasion.

Register or login to download the PPT

TACE: UPDATES ON COMBINATION THERAPY AND REAL-WORLD USE

The Barcelona Clinic Liver Cancer (BCLC) criteria consider intermediate stage (B) HCC patients with multinodular disease and preserved liver function and good performance status (ECOG PS 0) candidates for TACE.8 BCLC intermediate stage (C) patients are those with extrahepatic spread (EHS) or vascular invasion (VI) and have a reduction in performance status of (ECOG PS 1 or 2); they are considered candidates for systemic treatment.8

The prospective, observational OPTIMIS trial (NCT01933945) included 1650 patients with unresectable HCC planned for TACE.9 The study found that 32% (N=529) had BCLC stage C disease at study entry. Moreover, 7% (N=118) had EHS and 7% (N=123) had VI.9 In total, 39% of patients receiving TACE at study entry were ineligible for the procedure by international and regional treatment guidelines.9 Additionally, the trial found that the rate of disease progression increased with multiple TACE procedures.9 The majority of the patients (91%) who became TACE ineligible during the course of the study (N=507) were either not prescribed sorafenib or received it late.9

Another study by Professor Kudo and colleagues investigated the combination of transarterial chemoembolisation (TACE) and sorafenib for patients with unresectable HCC in the randomised, open-label TACTICS trial (NCT01217034).10 In total 156 patients with Child-Pugh score ≤7, ECOG performance status ≤1, no VI, no EHS, a maximum lesion size ≤10 cm and with ≤10 nodules were randomised to sorafenib plus conventional TACE (cTACE) vs cTACE alone. ).10 Kudo et al. reported a significantly increased median PFS (25.2 months) when compared to cTACE alone (13.5 months) (p=0.006), the number of OS events had not been reached and the median time to unTACEable progression (TTUP) was 26.7 months (sorafenib plus cTACE) vs 20.6 (cTACE).10 There were no unexpected toxicities.10

Figure 2. Data of selected Phase I ASCO 2018 HCC studies

BCLC=Barcelona Clinic Liver Cancer staging; CR=complete response; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; ORR=objective response rate; PD-1=Programmed Death 1; RP2D=recommended Phase 2 dose; pts=patients; TRAE=treatment-related adverse events.

" itemprop="thumbnailUrl">Figure 2. Data of selected Phase I ASCO 2018 HCC studies

BCLC=Barcelona Clinic Liver Cancer staging; CR=complete response; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; ORR=objective response rate; PD-1=Programmed Death 1; RP2D=recommended Phase 2 dose; pts=patients; TRAE=treatment-related adverse events.

" itemprop="thumbnailUrl" alt="ASCO2018 HCC ASCO18 hepatocellular carcinoma liver cancer keytruda pembrolizumab atezolizumab tecentriq cabozantinib levantinib ramucirumab REACH-2 CELESTIAL KEYNOTE-224" height="846" width="1500" srcset="https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1.png 1500w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1-300x169.png 300w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1-768x433.png 768w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1-1030x581.png 1030w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1-705x398.png 705w, https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO2018-HCC-ASCO18-hepatocellular-carcinoma-liver-cancer-keytruda-pembrolizumab-atezolizumab-tecentriq-cabozantinib-levantinib-ramucirumab-REACH-2-CELESTIAL-KEYNOTE-224-Ph1-1-450x254.png 450w" sizes="(max-width: 1500px) 100vw, 1500px">
©MediPaper Medical Communications Ltd

Figure 2. Data of selected Phase I ASCO 2018 HCC studies

BCLC=Barcelona Clinic Liver Cancer staging; CR=complete response; DCR=disease control rate; ECOG PS=Eastern Collaborative Oncology Group performance status; HCC=hepatocellular carcinoma; mo=months; NE=not evaluated; ORR= objective response rate; PD-1=Programmed Death 1; pts=patients; TRAE=treatment-related adverse events.

Register or login to download the PPT

ASCO 2018 HCC: IN THE PIPELINE

A single arm Phase II trial of icaritin, a highly selective oestrogen receptor a 36 (ERa36) modulator, in advanced HCC (N=70) found the drug to be safe (NCT01972672).11 No Grade 3 or higher drug-related adverse events were reported.11 Median OS was 254 days and disease control was achieved in 34.4% of patients.11 The study included subgroup analysis: the presence of high PD-L1 expression, interleukin (IL)-6 advantage, or a neutrophil-lymphocyte ratio (NLR)-advantage all showed better OS outcomes.11

A Phase Ib study of patients with unresectable or metastatic HCC who were naive to systemic treatment revealed that atezolizumab plus bevacizumab was well tolerated and had no new safety signals (NCT02715531).12 The combination therapy was associated with a 62% confirmed response rate in the selected study population.12

Another Phase I study investigated the combination of SHR-1210, a fully human IgG4 monoclonal antibody against PD-1, and VEGFR2 inhibitor apatinib in patients with several advanced GI cancers, including HCC refractory to standard therapy (NCT02942329).13 The investigators concluded the novel combination therapy had a manageable toxicity profile and showed early signs of clinical activity. Fourteen patients with HBV-related HCC were treated at different dosing levels and evaluable. The ORR and DCR were 50.0% and 85.7%, respectively.13

Finally, initial results from a Phase Ib trial combining the multikinase inhibitor lenvatinib with PD-1 MAb pembrolizumab in patients (N=13) with BCLC stage B (not amenable for TACE) or C, Child-Pugh class A, and ECOG PS ≤ 1 unresectable HCC (NCT03006926).14 The study revealed good safety profile and potential anti-tumour activity; with 6 partial responses and 6 stable diseases, the disease control rate (DCR) was 93%. The response assessment of 1 patient could not be evaluated.14

UNSUCCESSFUL CLINICAL DRUG CANDIDATES

Some ASCO 2018 HCC studies were not successful.

A Phase IB study showed that enzalutamide was not efficacious for patients with either androgen receptor (AR)-positive or AR-negative HCC.15 The trial also investigated the combination of enzalutamide plus sorafenib, but this combination was limited by drug-drug interactions (NCT02642913).15

A Phase II trial in the second-line setting for advanced HCC found that sorafenib plus doxorubicin after first-line failure on sorafenib did improve OS but was not well-tolerated.16 The investigators do not recommend further investigations of the combination therapy (NCT01840592).16

REFERENCES

  1. Zhu AX et al. J Clin Oncol 2018;36(suppl):Abstr 4003
  2. Abou-Alfa GK et al. J Clin Oncol 2018;36(suppl):Abstr 4019
  3. Rimassa L et al. J Clin Oncol 2018;36(suppl):Abstr 4090
  4. Kelley RK et al. J Clin Oncol 2018;36(suppl):Abstr 4088
  5. Zhu AX et al. J Clin Oncol 2018;36(suppl):Abstr 4020
  6. Feun LG et al. J Clin Oncol 2018;36(suppl):Abstr 4086
  7. Nakamura Y et al. J Clin Oncol 2018;36(suppl):Abstr 12094
  8. Forner A et al. Lancet 2018;391(10127):1301–14
  9. Peck-Radosavljevic M et al. J Clin Oncol 2018;36(suppl):Abstr 4018
  10. Kudo M et al. J Clin Oncol 2018;36(suppl):Abstr 4017
  11. Sun Y et al. J Clin Oncol 2018;36(suppl):Abstr 4077
  12. Stein S et al. J Clin Oncol 2018;36(suppl):Abstr 4074
  13. Xu JM et al. J Clin Oncol 2018;36(suppl):Abstr 4075
  14. Ikeda M et al. J Clin Oncol 2018;36(suppl):Abstr 4076
  15. Harding JJ et al. J Clin Oncol 2018;36(suppl):Abstr 4083
  16. El Dika IH et al. J Clin Oncol 2018;36(suppl):Abstr 4080

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2018 MediPaper Medical Communications Ltd. – ASCO 2018 HCC Track – #ASCO18 Hepatocellular Carcinoma – ASCO18 Liver Cancer

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

Dosing issues with DOACs in Asian real world setting

Dosing issues with DOACs in Asian real world setting

https://ftp.medi-paper.com/wp-content/uploads/2021/12/Dosing-issues-with-DOACs-in-Asian-real-world-setting.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-12-23 18:58:462022-02-18 10:04:38Dosing issues with DOACs in Asian real world setting
Sotorasib approved as the first targeted therapy for Lung Cancer

Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer

https://ftp.medi-paper.com/wp-content/uploads/2021/11/Sotorasib-approved-as-the-first-targeted-therapy-for-Lung-Cancer.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-11-22 11:35:262022-01-13 13:51:11Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer
Amivantamab in combination with Lazertinib showed efficacy in NSCLC

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2021/11/Amivantamab-in-combination-with-Lazertinib-showed-efficacy-in-NSCLC.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-11-22 11:05:252022-01-11 11:49:24Amivantamab in combination with Lazertinib showed efficacy in NSCLC
ASCO GI Webinar Update on NET and HCC_Ipsen

ASCO GI Webinar: Update on NET and HCC

https://ftp.medi-paper.com/wp-content/uploads/2021/10/ASCO-GI-Webinar-Update-on-NET-and-HCC_Ipsen-1.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-10-07 11:48:162021-11-04 09:28:12ASCO GI Webinar: Update on NET and HCC
ASCO 2021 Liver Cancer Update

ASCO 2021 Liver Cancer Update

https://ftp.medi-paper.com/wp-content/uploads/2021/06/ASCO-2021-Liver-Cancer-Update.jpg 1024 1917 Coco Chong https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Coco Chong2021-06-11 10:29:242021-06-17 14:03:45ASCO 2021 Liver Cancer Update
Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

https://ftp.medi-paper.com/wp-content/uploads/2021/06/Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer.jpg 1024 1917 Coco Chong https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Coco Chong2021-06-11 09:31:122021-11-04 09:44:10Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer
Advancing care for advanced renal cell carcinoma choosing the optimal therapy for you patients_dr Darren Poon

Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients

https://ftp.medi-paper.com/wp-content/uploads/2021/04/Advancing-care-for-advanced-renal-cell-carcinoma-choosing-the-optimal-therapy-for-you-patients_dr-Darren-Poon.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-19 13:32:492021-06-11 11:12:45Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients
the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

The evolving role of NK1 in CINV management

https://ftp.medi-paper.com/wp-content/uploads/2021/04/the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-e1618546071115.jpg 1024 1917 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2021-04-16 09:17:092021-04-20 13:49:08The evolving role of NK1 in CINV management
Lung Cancer Update April 2021

Lung Cancer Update April 2021

https://ftp.medi-paper.com/wp-content/uploads/2021/04/Lung-Cancer-Update-April-2021.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-08 16:28:082021-07-22 14:10:19Lung Cancer Update April 2021
Abemaciclib A review of the evidence through clinical case

Abemaciclib: A review of the evidence through clinical cases

https://ftp.medi-paper.com/wp-content/uploads/2021/03/Abemaciclib-A-review-of-the-evidence-through-clinical-case.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-03-25 15:09:132021-11-04 12:19:55Abemaciclib: A review of the evidence through clinical cases
The Role of Patient Blood Management for Inflammatory Bowel Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

https://ftp.medi-paper.com/wp-content/uploads/2021/02/The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01.png 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-27 19:09:322021-07-22 14:11:50The Role of Patient Blood Management for Inflammatory Bowel Disease
Breast-Cancer-Update-2021

Breast cancer update January 2021

https://ftp.medi-paper.com/wp-content/uploads/2021/01/Breast-Cancer-Update-2021.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-01 16:44:392021-02-02 14:55:17Breast cancer update January 2021
Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

https://ftp.medi-paper.com/wp-content/uploads/2021/01/Osimertinib-approved-as-the-first-adjuvant-treatment-for-early-non-small-cell-lung-cancer.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-28 11:43:032021-02-02 14:56:44Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer
Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

https://ftp.medi-paper.com/wp-content/uploads/2021/01/Increasing-dose-frequency-of-lanreotide-autogel-injections-in-neuroendocrine-tumours.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-27 11:18:282021-07-22 14:18:09Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours
cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women

Cabotegravir and rilpivirine intramuscular combination safe in women

https://ftp.medi-paper.com/wp-content/uploads/2020/12/cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 16:25:172021-03-02 17:51:19Cabotegravir and rilpivirine intramuscular combination safe in women
hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment

HCV-infected kidneys safe for transplantation with antiviral treatment

https://ftp.medi-paper.com/wp-content/uploads/2020/12/hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 15:46:392021-03-02 17:51:24HCV-infected kidneys safe for transplantation with antiviral treatment
baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema

Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA

https://ftp.medi-paper.com/wp-content/uploads/2020/12/baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 12:11:172021-03-02 17:51:13Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA
U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

https://ftp.medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2020-12-08 18:00:012020-12-10 20:19:55US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
detecting metastases with psma pet in prostate cancer

Detecting metastases with PSMA-PET in prostate cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172020-12-11 15:12:41Detecting metastases with PSMA-PET in prostate cancer
asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/12/asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-07 17:20:022020-12-11 14:24:21ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
Sotorasib for the treatment of KRASG12C-mutated lung cancer

Sotorasib for the treatment of KRASG12C mutated lung cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/10/Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 10:16:382020-10-15 11:45:13Sotorasib for the treatment of KRASG12C mutated lung cancer
Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/10/Capmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 09:46:042020-10-15 11:41:25Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer
Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/09/Selpercatinib-displays-efficacy-in-RET-fusion-positive-non-small-cell-lung-cancer-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 21:04:252020-09-07 23:03:18Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

First liquid biopsy for NSCLC to receive FDA approval

https://ftp.medi-paper.com/wp-content/uploads/2020/09/First-liquid-biopsy-for-NSCLC-to-receive-FDA-approval-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 10:09:062020-09-08 09:56:03First liquid biopsy for NSCLC to receive FDA approval
ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

ESMO releases the first guideline on NGS testing in cancers

https://ftp.medi-paper.com/wp-content/uploads/2020/09/ESMO-releases-the-first-guideline-on-NGS-testing-in-cancers-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 09:36:352020-09-08 08:52:38ESMO releases the first guideline on NGS testing in cancers
residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

https://ftp.medi-paper.com/wp-content/uploads/2020/08/residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 16:18:002020-08-17 16:56:12Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance
updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

https://ftp.medi-paper.com/wp-content/uploads/2020/08/updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 14:41:322020-08-25 14:37:07Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society
Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

Lower-risk MDS patients benefit from novel drug, imetelstat

https://ftp.medi-paper.com/wp-content/uploads/2020/07/Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat.jpg 844 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:512020-08-11 09:56:13Lower-risk MDS patients benefit from novel drug, imetelstat
Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/07/Carboplatin-plus-paclitaxel-to-be-the-new-standard-of-care-for-anal-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:482020-08-11 09:52:36Carboplatin plus paclitaxel to be the new standard of care for anal cancer
ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

ASCO 2020 Lung, Breast, and Liver Cancer Update

https://ftp.medi-paper.com/wp-content/uploads/2020/06/ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717.jpg 794 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-06-30 09:37:482020-09-24 12:33:53ASCO 2020 Lung, Breast, and Liver Cancer Update
Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

https://ftp.medi-paper.com/wp-content/uploads/2020/04/gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly.png 850 1500 陳穎樂醫生 https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png 陳穎樂醫生2020-04-30 14:03:452021-06-23 17:15:43Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong
Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

https://ftp.medi-paper.com/wp-content/uploads/2020/02/Capivasertib-added-to-fulvestrant-improves-progression-free-survival-in-advanced-breast-cancer-patients.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-19 23:37:222020-02-21 10:24:39Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

https://ftp.medi-paper.com/wp-content/uploads/2019/12/Capivasertib-combined-with-paclitaxel-improves-survival-of-metastatic-triple-negative-breast-cancer-patients-e1582170747234.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-11 17:30:382020-02-11 23:17:00Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients
Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

https://ftp.medi-paper.com/wp-content/uploads/2019/12/Olaparib-plus-Bevacizumab-as-Maintenance-Therapy-in-Ovarian-Cancer.jpg 844 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-24 16:32:552020-01-24 16:40:07Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer
ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

https://ftp.medi-paper.com/wp-content/uploads/2020/01/ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3-scaled.jpg 1056 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-12 23:33:152020-01-13 10:41:47Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

https://ftp.medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-.png 1000 750 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-12 14:12:322019-06-12 16:51:35ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

https://ftp.medi-paper.com/wp-content/uploads/2019/05/ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-03 16:53:572019-06-04 14:34:55ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

Venetoclax FDA approved for CLL and SLL

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-15 16:19:292019-05-23 12:36:08Venetoclax FDA approved for CLL and SLL

FDA approves avelumab plus axitinib for renal cell carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-05-14 16:22:572019-05-22 22:49:14FDA approves avelumab plus axitinib for renal cell carcinoma

Ramucirumab FDA approved for hepatocellular carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-10 16:24:042019-05-23 11:58:38Ramucirumab FDA approved for hepatocellular carcinoma

T-DM1 FDA approved for early breast cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-03 16:24:342019-05-22 22:14:15T-DM1 FDA approved for early breast cancer

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-02 16:25:032019-05-22 22:14:36Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

https://ftp.medi-paper.com/wp-content/uploads/2019/04/Can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-26 20:05:262019-04-26 20:12:32Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-26 00:34:542019-04-26 00:38:58Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

https://ftp.medi-paper.com/wp-content/uploads/2019/04/KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-24 18:22:142019-04-24 18:22:14KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer
Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

https://ftp.medi-paper.com/wp-content/uploads/2019/04/Atezolizumab-with-or-without-cobimetinib-vs-regorafenib-for-previously-treated-metastatic-colorectal-cancer-IMblaze370.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-22 21:21:372019-04-22 21:57:04Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

Palbociclib approved for the treatment of male breast cancer 

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 16:13:232019-04-22 21:56:34Palbociclib approved for the treatment of male breast cancer 

Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 14:35:132019-04-22 21:56:48Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-23 09:39:402019-03-23 09:41:21Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-09 23:15:272019-03-09 23:15:27Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer
Immunoncology I-O drugs and immunotherapy for renal cancer RCC

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2019/02/Immunoncology-I-O-drugs-and-immunotherapy-for-renal-cancer-RCC-.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-03-05 11:13:432019-03-07 14:27:09Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-23 15:05:352019-03-08 17:00:25Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

Pembrolizumab FDA approved for adjuvant treatment of melanoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-16 14:55:172019-03-07 14:56:16Pembrolizumab FDA approved for adjuvant treatment of melanoma

Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-21 23:16:452019-04-22 16:24:29Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

Cabozantinib FDA approved in HCC patients failing sorafenib

https://ftp.medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-17 10:35:362019-02-18 13:23:29Cabozantinib FDA approved in HCC patients failing sorafenib
Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

https://ftp.medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-14 15:36:172019-01-14 15:43:55Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 16:16:402018-12-27 16:16:40Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 15:51:482018-12-27 15:53:57Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-22 16:54:192018-12-22 16:54:19Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-21 15:19:112018-12-21 15:32:40Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-11 13:21:272018-12-11 13:22:23Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

https://ftp.medi-paper.com/wp-content/uploads/2018/12/Depositphotos_159314198_xl-2015.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-05 22:00:342018-12-13 13:22:27MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab
TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

https://ftp.medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-29 15:08:432018-11-29 15:11:38Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-28 17:00:152018-11-28 18:03:05TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

FDA Approves Truxima as Biosimilar to Rituxan

https://ftp.medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-28 14:34:182019-11-12 15:16:57FDA Approves Truxima as Biosimilar to Rituxan

Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 23:17:102018-11-23 23:24:03Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 22:43:422018-11-23 22:43:42Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/11/Y90-TARE-TheraSphere-The-Emerging-Role-of-Yttrium-90-in-Primary-and-Metastatic-Liver-Cancer..jpg 844 1500 Adrian YIP https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Adrian YIP2018-11-22 22:48:462018-12-11 10:42:29The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:38:102018-11-21 23:49:14Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

https://ftp.medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:01:122018-11-21 23:05:07Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas
Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

https://ftp.medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

https://ftp.medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-19 11:11:132018-11-19 13:45:58Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

Lorlatinib FDA approved for metastatic ALK-positive NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-06 11:30:052018-11-06 11:32:59Lorlatinib FDA approved for metastatic ALK-positive NSCLC
ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

https://ftp.medi-paper.com/wp-content/uploads/2018/10/esmo-2018-hcc-esmo18-liver-cancer-esmo-2018-hepatocellular-carcinoma-hepatobilliary-cholangiocarcinoma-btc-.png 1001 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-03 17:30:562018-11-05 12:51:54ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-01 10:49:132018-11-01 10:53:51Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC
Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

Management of Immune-Mediated Hepatitis: a Case Report

https://ftp.medi-paper.com/wp-content/uploads/2018/04/management-irAE-hepatitis-manage-immune-mediated-hepatitis-immunotherapy-I-O-immunooncology-immune-induced-hepatitis--e1542867473384.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-10-31 05:53:132018-11-22 15:01:08Management of Immune-Mediated Hepatitis: a Case Report

PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/10/1539706020_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-18 20:50:302018-10-18 21:12:52PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer
innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

https://ftp.medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/10/IMpower133-first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer-e1539272789598.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-11 23:48:162018-10-17 11:29:19IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Pembrolizumab plus chemotherapy effective in squamous NSCLC

Pembrolizumab plus chemotherapy effective in squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/10/Pembrolizumab-plus-chemotherapy-effective-in-squamous-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-08 00:43:132018-10-17 11:27:05Pembrolizumab plus chemotherapy effective in squamous NSCLC
Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/10/Ipilimumab-plus-nivolumab-for-persistent-or-recurrent-ovarian-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-07 00:13:112018-10-17 11:26:28Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer
Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/10/Brigatinib-prolongs-PFS-compared-to-crizotinib-in-ALK-Positive-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 17:27:422018-10-17 11:25:12Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

https://ftp.medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 15:24:252018-10-17 11:23:17CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

https://ftp.medi-paper.com/wp-content/uploads/2018/10/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-03 12:53:562018-10-17 11:20:52PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/10/JAVELIN-Lung-200-avelumab-vs-docetaxel-in-patients-with-pretreated-advanced-non-small-cell-lung-cancer-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-02 01:01:252018-10-17 11:18:32JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 23:18:162018-10-17 11:17:46Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R CLL or SLL

https://ftp.medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:33:572018-09-25 17:46:01Duvelisib FDA approved for adult patients with R/R CLL or SLL
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Duvelisib FDA approved for adult patients with R/R follicular lymphoma

https://ftp.medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:20:472018-09-25 17:36:29Duvelisib FDA approved for adult patients with R/R follicular lymphoma
Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Front-line-atezolizumab-plus-chemotherapy-improves-PFS-in-NSCLC.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 10:01:562018-09-25 10:11:35Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/09/First-line-osimertinib-vs-EGFR-TKI-in-Asian-patients-with-advanced-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-24 13:24:282018-09-24 15:25:11First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC
Early breast cancer treatment in China remains conservative

Early breast cancer treatment in China remains conservative

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Early-breast-cancer-treatment-in-China-remains-conservative.jpg 1000 1510 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-23 23:35:002018-09-23 23:39:31Early breast cancer treatment in China remains conservative
immuno-oncology I-O treatment for the irAE Rash©MediPaper Medical Communications Ltd

ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

https://ftp.medi-paper.com/wp-content/uploads/2018/06/immuno-oncology-I-O-treatment-for-the-irAE-Rash.png 786 752 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-21 01:15:492018-09-21 13:29:44ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash
Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

https://ftp.medi-paper.com/wp-content/uploads/2018/02/Prof-Stefan-Kasper-on-I-O-in-EXTREME-ineligible-Head-and-Neck-Cancer-I-O-in-SCCHN-with-focus-on-EXTREME-ineligible-Patients-and-the-future-directions-of-combination-immunotherapy.jpg 924 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-19 12:54:212018-09-21 14:01:09Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN
Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

Camrelizumab anti-PD-1 with or without chemotherapy for NPC

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Camrelizumab-anti-PD-1-with-or-without-Chemotherapy-for-NPC-e1537238880148.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-18 09:52:592018-09-18 09:55:32Camrelizumab anti-PD-1 with or without chemotherapy for NPC
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia

https://ftp.medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-14 14:20:432018-09-14 14:20:43Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer©MediPaper Medical Communications Ltd

I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

https://ftp.medi-paper.com/wp-content/uploads/2017/11/Adrian-TSE-HKIOC-irAE-pneumonitis-lung-immunotherapy-induced-pneumonitis-I-O-Immuno-Oncology-cannonball-metastases-cancer.jpg 838 798 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-14 13:13:492018-09-21 13:56:54I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis
MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

Venetoclax FDA label updated to include Minimal Residual Disease negativity data

https://ftp.medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:26:092018-09-14 14:25:02Venetoclax FDA label updated to include Minimal Residual Disease negativity data
Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Quizartinib-Receives-Orphan-Drug-Designation-for-FLT3-Mutated-AML-in-Japan.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:21:342018-09-12 22:21:34Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作 醫學作家香港© Eraxion / 123RF Stock Photo

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Lung-Cancer-Capmatinib-plus-gefitinib-promising-in-MET-dysregulated-NSCLC-MediPaper-Medical-Communications-Medical-Writer-Hong-Kong-醫學寫作-醫學作家香港.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-11 21:33:342018-09-11 21:48:36Capmatinib plus gefitinib promising in MET-dysregulated NSCLC
CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer© Royaltystockphoto / 123RF Stock Photo

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/09/CAR-TCR-Summit-2018-Preliminary-first-in-human-data-with-CAR-Claudin18.2-T-in-gastric-and-pancreatic-cancer.jpg 1054 1505 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-09 09:38:282018-09-09 09:38:28CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer
DRIVER connects cancer patients in China and the United States to the best care© Kentoh / 123RF Stock Photo

DRIVER connects cancer patients in China and the United States to the best care

https://ftp.medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg 994 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care
Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

https://ftp.medi-paper.com/wp-content/uploads/2018/08/Blood-based-TMB-assay-predicts-response-to-atezolizumab-in-NSCLC-patients.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-31 07:42:492018-08-31 14:33:03Plasma TMB predicts response to atezolizumab in NSCLC patients
First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation© luchschen / 123RF Stock Photo

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

https://ftp.medi-paper.com/wp-content/uploads/2018/08/First-in-Class-Oncology-Vaccine-BIL06v-Starts-Phase-1-Evaluation.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-22 11:48:172018-08-27 09:35:59First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation
Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

Pembrolizumab and atezolizumab USPIs updated by FDA

https://ftp.medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 12:10:412018-08-21 13:18:15Pembrolizumab and atezolizumab USPIs updated by FDA
Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

https://ftp.medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 11:24:202018-08-23 10:48:02Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 10:34:252018-08-21 11:37:56Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC
Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

https://ftp.medi-paper.com/wp-content/uploads/2018/08/Talazoparib-in-advanced-breast-cancer-patients-with-a-germline-BRCA12-mutation.jpg 687 1030 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-19 01:07:502018-08-21 21:55:19Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation
CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/08/CheckMate-032-Nivolumab-ipilimumab-metastatic-esophagogastric-cancer.jpg 667 1000 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 23:22:562018-08-19 01:08:26CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Lenvatinib FDA approved for 1st-line treatment of HCC

https://ftp.medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 15:50:342018-08-21 22:35:40Lenvatinib FDA approved for 1st-line treatment of HCC
Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China©Alex011973 / 123RF Stock Photo

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

https://ftp.medi-paper.com/wp-content/uploads/2018/08/Pan-EGFR-TKI-pirotinib-has-commenced-into-Phase-II-clinical-testing-in-China.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-13 23:09:022018-09-07 21:59:21Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

https://ftp.medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-09 00:58:382018-08-12 12:28:54FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

https://ftp.medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-01 09:21:032018-08-12 16:46:52Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-31 15:44:032018-07-31 15:45:41Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3© srr283/123RF

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

https://ftp.medi-paper.com/wp-content/uploads/2018/08/T790M-osimertinib-nsclc-CNS-brain-metastasis-Osimertinib-in-patients-With-T790M-Positive-Advanced-Non-Small-Cell-Lung-Cancer-and-brain-metastases-AURA3.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 23:43:262018-08-20 12:36:41Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)
Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/08/Anti-PD1-with-Cemiplimab-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-26 23:44:412018-08-22 23:58:36Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-23 11:33:402018-07-30 10:43:08Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

Filgrastim-aafi FDA approved as Filgrastim Biosimilar

https://ftp.medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-20 10:58:232018-08-11 23:55:01Filgrastim-aafi FDA approved as Filgrastim Biosimilar
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ribociclib FDA label updated to include pre- and perimenopausal women

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-19 01:01:572018-07-30 10:42:22Ribociclib FDA label updated to include pre- and perimenopausal women
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

https://ftp.medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-17 10:14:112018-07-30 10:42:09Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer© abhijith3747/123RF

EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/08/EBV-pembrolizumab-gastric-cancer-MSI-H-pembrolizumab-gastric-cancer-CPS-pembrolizumab-gastric-cancer-MSI-EBV-CPS-predict-pembrolizumab-outcome-in-gastric-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-16 14:03:432018-08-31 08:15:52EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-11 20:52:132018-07-30 10:41:58Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-02 22:14:052018-07-30 10:41:23Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-nsclc-immunotherapy-ASCO18-lung-cancer-pembrolizumab-avelumab-nivolumab-duravalumab-ipilimumab-osimertinib-dacomitinib-lorlatinib-crizotinib-alectinib-keytruda-KEYNOTE-CheckMate-JAVELIN-IMpower.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-25 18:22:252018-08-21 11:43:54ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

https://ftp.medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-19 14:01:322018-07-30 10:40:51FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo©eraxion / 123RF Stock Photo

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

https://ftp.medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-breast-cancer-TNBC-MBC-ABC-ASCO18-PHEREXA-D-CARE-ABCSG-18-ASTRRA-TEXT-SOFT-MONARCH-2-MONALEESA-3-SANDPIPER-BOLERO-6-TOPACIO-KEYNOTE-162-TONIC-TOPACIO-GeparNeuvo.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-06-19 09:02:512018-06-19 23:57:08ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:56:042018-07-30 10:40:22Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:42:142018-07-30 10:40:10FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-13 21:59:012018-07-30 10:39:54FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approves venetoclax in 2nd-line for patients with CLL or SLL

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-09 11:25:082018-09-25 17:51:30FDA approves venetoclax in 2nd-line for patients with CLL or SLL
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-06 16:07:462018-08-11 23:55:46FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclcbravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/05/IMPower150-Reck-Socinski-ELCC-AACR-2018-firstline-atezolizumab-bevacizumab-chemotherapy-non-squamous-nsclc.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-10 16:19:462018-05-24 09:31:31AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC
US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018

https://ftp.medi-paper.com/wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-30 13:35:562018-07-30 11:42:21Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826Hywards / 123RF Stock Photo

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

https://ftp.medi-paper.com/wp-content/uploads/2018/04/First-line-Nivolumab-Ipilimumab-in-TMB-high-NSCLC-front-line-immunotherapy-for-non-small-cell-lung-cancer-CheckMate-227-NCT02477826.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-21 10:30:432018-05-24 09:37:03Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-19 13:36:062018-07-30 11:15:04FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhikrishnacreations / 123RF Stock Photo

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

https://ftp.medi-paper.com/wp-content/uploads/2018/04/NCT02578680-Keynote189-pembrolizumab-chemotherapy-nsclc-NEJM-Leena-Gandhi.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-19 01:27:262018-05-24 09:37:16Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-16 13:59:012018-07-30 11:50:31Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

https://ftp.medi-paper.com/wp-content/uploads/2018/04/Keynote-042-Keynote-024-pembrolizumab-nsclc-keytruda-nsclc-non-squamous-squamous-PD-L1-expression-1-20-50-Tony-Mok-MD-NCT02220894-Pembrolizumab-effective-in-frontline-NSCLC-with-low-PD-L1-expression.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-10 20:15:112018-05-24 09:37:32Pembrolizumab effective in frontline NSCLC with low PD-L1 expression
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

Everolimus suspension approved in TSC-associated partial-onset seizures

https://ftp.medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-10 14:07:302018-07-30 14:22:09Everolimus suspension approved in TSC-associated partial-onset seizures
Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

https://ftp.medi-paper.com/wp-content/uploads/2018/02/Herbert-Loong-on-irAEs-Immunotherapy-I-O-and-New-Onset-Diabetes-or-immune-mediated-diabetes.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-06 09:00:412018-08-11 23:56:01I-O in Special Populations: Diabetes and Concomitant Steroids
Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

https://ftp.medi-paper.com/wp-content/uploads/2018/04/Crizotinib-beneficial-for-East-Asian-NSCLC-patients-with-ROS1-alterations-crizotinib-asian-crizotinib-ros1-crizotinib-asian-nsclc-patients-crizotinib-asian-non-small-cell-lung-cancer-patients-e1522913753323.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-04 16:00:112018-04-19 13:57:57Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Death due to cancer on the decline for most tumours in Europe

https://ftp.medi-paper.com/wp-content/uploads/2018/03/1522336566_Oncology-Breast-CNS-Chemotherapy-Endocrine-GI-GU-Geriatric-Gynecologic-GYN-OB-Head-and-Neck-Haematology-Immunotherapy-Lung-Melanoma-Skin-NET-Paediatric-Pathology-Sarcoma-Surgery-Targeted-Therapy-Translational-03.jpg 277 450 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 11:03:502018-08-10 11:57:59Death due to cancer on the decline for most tumours in Europe
immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

https://ftp.medi-paper.com/wp-content/uploads/2018/03/nivolumab-npc-opdivo-nasopharyngeal-carcinoma-brigette-ma-CUHK-phase-II-nci-9742-study-JCO-journal-of-clinical-oncology.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 09:20:312018-05-24 09:38:41Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)
©aquir / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

https://ftp.medi-paper.com/wp-content/uploads/2018/05/1526019694_US-FDA-Oncology-Haematology-Drug-Approvals-e1537929700820.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-03-29 14:21:342018-09-25 17:51:10FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%
Making sense of immunotherapy in NSCLC

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

https://ftp.medi-paper.com/wp-content/uploads/2018/03/Making-sense-of-immunotherapy-in-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-26 16:06:282018-07-31 23:06:54Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)
manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

https://ftp.medi-paper.com/wp-content/uploads/2017/11/image.png 852 1471 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-29 22:12:232018-04-19 10:46:51Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects
2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Do you know your lifetime risk on Pancreatic Cancer?

https://ftp.medi-paper.com/wp-content/uploads/2016/11/2016-Pancreatic-Cancer-medipaper-medical-communications-medical-writer-hire-healthcare-writers-hong-kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-20 12:29:422018-02-09 14:08:00Do you know your lifetime risk on Pancreatic Cancer?
HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

https://ftp.medi-paper.com/wp-content/uploads/2017/10/HKBCF-luminal-breast-cancer-can-cdk46-inhibition-by-palbociclib-improve-on-chemotherapy-medipaper-medical-writer-hong-kong.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-10-25 22:58:382018-02-09 14:08:00Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Pembrolizumab approved for advanced gastric cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:33:522018-07-26 15:04:47Pembrolizumab approved for advanced gastric cancer
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

Nivolumab approved for sorafenib-refractory HCC

https://ftp.medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:21:412018-07-26 11:42:35Nivolumab approved for sorafenib-refractory HCC
Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

https://ftp.medi-paper.com/wp-content/uploads/2017/09/Nivolumab-Renal-Cell-Cancer-Symposium-Highlight.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-19 23:04:512018-08-11 23:56:17Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
adjuvant hormonal therapy

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

https://ftp.medi-paper.com/wp-content/uploads/2017/08/adjuvant-hormonal-therapy.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-07-05 22:46:312018-02-09 14:08:00Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

Interested in Attending an Immunooncology Conference?

https://ftp.medi-paper.com/wp-content/uploads/2017/02/2017-CICS-immunooncology-annual-meeting-oncology-medical-writer-medipaper-medical-communications.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-06-21 16:05:482018-02-09 14:08:00Interested in Attending an Immunooncology Conference?
esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

https://ftp.medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-Breast-Cancer-Palbociclib-Ribociclib-Abemaciclib-data-MediPaper-Medical-Writer-e1478671413852.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-11-09 16:00:442018-05-11 17:14:06ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

https://ftp.medi-paper.com/wp-content/uploads/2016/08/PD-L1-Biomarker-for-Response-DAKO-22C3-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-26 14:00:352018-05-11 17:21:18PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data
Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

https://ftp.medi-paper.com/wp-content/uploads/2016/10/Biomarkers-Ipilimumab-Treatment-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-24 10:12:072018-05-11 17:18:58Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies
ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data – Download the PPT

https://ftp.medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-ipilimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-11 11:10:102018-05-11 17:28:19ESMO16 Ipilimumab data – Download the PPT
ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data – Download the PPT

https://ftp.medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-pembrolizumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 21:08:122018-05-11 17:28:28ESMO16 Pembrolizumab data – Download the PPT
ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT

https://ftp.medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-durvalumab-avelumab-tremelimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 10:30:512018-05-11 17:28:38ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT
ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data – Download the PPT

https://ftp.medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-atezolizumab-data-medipaper.jpg 665 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 17:50:232018-05-11 17:28:52ESMO16 Atezolizumab data – Download the PPT
ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data – Download the PPT

https://ftp.medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-nivolumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 16:30:582018-05-11 17:29:00ESMO16 Nivolumab data – Download the PPT
cancer awareness improves outcome medipaper medical communications

Cancer symptom awareness linked to survival

https://ftp.medi-paper.com/wp-content/uploads/2016/09/cancer-awareness-improves-outcome-medipaper-medical-communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-30 21:33:432018-02-09 13:51:10Cancer symptom awareness linked to survival
2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

https://ftp.medi-paper.com/wp-content/uploads/2016/09/2016-asco-ovarian-cancer-guidelines-neo-adjuvant-chemotherapy-medipaper-medical-communications-e1478394814429.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-27 21:53:422018-02-09 14:07:58ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated
IMM-101 plus gemcitabine-medipaper medical communications BW

IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

https://ftp.medi-paper.com/wp-content/uploads/2016/09/IMM-101-plus-gemcitabine-medipaper-medical-communications_medical_writer_hong_kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-25 00:19:582018-02-09 13:51:09IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer
palbociclib-first-in-class

Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

https://ftp.medi-paper.com/wp-content/uploads/2016/04/palbociclib-first-in-class.jpg 662 1095 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-17 00:46:162018-05-11 17:13:52Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor
Ki67 breast cancer medical writer epotomics

Ki67 in Breast Cancer: an overview

https://ftp.medi-paper.com/wp-content/uploads/2016/04/Ki67-breast-cancer-medical-writer-epotomics-com.png 998 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-06 00:07:072018-05-11 17:15:08Ki67 in Breast Cancer: an overview
ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

ASCO16 Ribociclib & Abemaciclib Data

https://ftp.medi-paper.com/wp-content/uploads/2016/06/ribociclib-abemaciclib-ASCO2016-Data-MediPaper-Medical-Communications.jpg 1033 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-05 23:30:482018-05-11 17:17:01ASCO16 Ribociclib & Abemaciclib Data
ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Palbociclib-Data-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-04 22:51:302018-05-11 17:16:17ASCO16 palbociclib (Ibrance©) Data
ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

https://ftp.medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Azelumab-Durvalumab-and-Tremelimumab-Data.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-03 11:57:432018-05-11 17:25:17ASCO16 Avelumab, Durvalumab, and Tremelimumab
asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/06/asco-2016-atezolizumab-data.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-02 15:15:132018-05-11 17:25:04ASCO16 Atezolizumab (Tecentriq©) Data
ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/05/ASCO2016-ipilimumab-data-MediPaper-Medical-Communications.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-31 13:05:442018-05-11 17:22:00ASCO16 Ipilimumab (Yervoy©) Data
asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/05/asco-2016-pembrolizumab.jpg 851 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:23:322018-05-11 17:22:45ASCO16 Pembrolizumab (Keytruda©) Data
PreviousNext
5 replies

Trackbacks & Pingbacks

  1. Ramucirumab FDA approved for hepatocellular carcinoma | MediPaper says:
    23rd May 2019 at 11:58 AM

    […] FDA approval was based on data of the multinational, double-blind, placebo-controlled, multicentre REACH‑2 (NCT02435433) study that randomised 292 advanced HCC patients with AFP ≥400 ng/mL and disease […]

    Log in to Reply
  2. Ramucirumab FDA approved for hepatocellular carcinoma | MediNews Asia says:
    23rd May 2019 at 11:50 AM

    […] FDA approval was based on data of the multinational, double-blind, placebo-controlled, multicentre REACH‑2 (NCT02435433) study that randomised 292 advanced HCC patients with AFP ≥400 ng/mL and disease […]

    Log in to Reply
  3. Cabozantinib FDA approved in HCC patients failing sorafenib says:
    17th January 2019 at 10:35 AM

    […] randomised, double-blind, placebo-controlled, multicentre CELESTIAL trial randomised 707 HCC patients with Child-Pugh Class A liver impairment and previously treated […]

    Log in to Reply
  4. ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised says:
    5th November 2018 at 1:03 PM

    […] the Phase III, open-label, randomised REFCLECT (NCT01761266) study showed non-inferiority for levantinib -a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT- when compared to […]

    Log in to Reply
  5. ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised says:
    3rd November 2018 at 10:35 PM

    […] sorafenib treatment in patients with advanced HCC from the Phase III REACH (NCT01140347) and REACH-2 studies (NCT02435433).2Zhu AX, et al. Ann Oncol 2018;29(8):mdy282.006 Patients in the REACH-2 were […]

    Log in to Reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2018 MediPaper Medical Communications Ltd. – ASCO 2018 HCC Track – #ASCO18 Hepatocellular Carcinoma – ASCO18 Liver Cancer

Therapeutic Areas

Login

or
Login with Google
Login with Facebook
Login with Twitter
Login with LinkedIn
  • Register
  • Lost your password?

Or, sign up for our newsletter


Interesting links

Here are some interesting links for you! Enjoy your stay :)
© 2016-2022 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
FDA approves venetoclax in 2nd-line for patients with CLL or SLLRibociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug AgencyRibociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug AgencyFDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with...
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only
Copy link
CopyCopied
Powered by Social Snap
MediPaper Medical Communications Agency Hong Kong Blog